Department of Surgery, Division of Surgical Oncology, University of Tennessee Health Science Center, Memphis, TN, USA.
Ann Surg Oncol. 2021 Jan;28(1):492-501. doi: 10.1245/s10434-020-08824-9. Epub 2020 Jul 11.
Although advocated by some, minimally invasive adrenalectomy (MIA) for adrenocortical carcinoma (ACC) is controversial. Moreover, the oncologic implications for patients requiring conversion to an open procedure during attempted MIA for ACC are not extensively reported.
The National Cancer Database was queried for patients undergoing resection for ACC. Overall survival (OS) for patients undergoing successful MIA was compared with those requiring conversion, and additionally evaluated with a multivariable Cox regression analysis including other factors associated with OS. After propensity matching, those experiencing conversion were further compared with patients who underwent planned open resection.
Among 196 patients undergoing attempted MIA for ACC, 38 (19.4%) required conversion. Independent of 90-day postoperative mortality, conversion was associated with significantly reduced OS compared with successful MIA (median 27.9 months versus not reached, p = 0.002). Even for tumors confined to the adrenal, conversion was associated with worse median OS compared with successful MIA (median 34.2 months versus not reached, p = 0.003). After propensity matching for clinicopathologic covariates to establish well-balanced cohorts (N = 38 per group), patients requiring conversion during MIA had significantly worse OS than those having planned open resection (27.9 months versus 50.5 months, p = 0.020). On multivariable analysis for predictors of OS, conversion during MIA (HR 2.32, p = 0.003) was independently associated with mortality.
ACC is a rare tumor for which adequate oncologic resection is the only chance for cure. Given the relatively high rate of conversion and its associated inferior survival, open resection should be considered standard of care for known or suspected ACC.
虽然有一些人提倡,但微创肾上腺切除术(MIA)治疗肾上腺皮质癌(ACC)仍存在争议。此外,对于在尝试 MIA 治疗 ACC 时需要转为开放手术的患者,其肿瘤学影响尚未广泛报道。
国家癌症数据库被查询接受 ACC 切除术的患者。成功进行 MIA 的患者的总生存(OS)与需要转换的患者进行比较,并通过多变量 Cox 回归分析进行评估,包括与 OS 相关的其他因素。在倾向匹配后,进一步将转换的患者与接受计划开放性切除的患者进行比较。
在 196 例接受尝试 MIA 治疗 ACC 的患者中,有 38 例(19.4%)需要转换。独立于 90 天术后死亡率,与成功的 MIA 相比,转换与明显降低的 OS 相关(中位 27.9 个月与未达到,p=0.002)。即使肿瘤局限于肾上腺,与成功的 MIA 相比,转换也与更差的中位 OS 相关(中位 34.2 个月与未达到,p=0.003)。在进行临床病理协变量的倾向匹配以建立平衡良好的队列后(每组 38 例),MIA 期间需要转换的患者的 OS 明显差于计划进行开放性切除的患者(27.9 个月与 50.5 个月,p=0.020)。在多变量分析中,OS 的预测因素,MIA 期间的转换(HR 2.32,p=0.003)与死亡率独立相关。
ACC 是一种罕见的肿瘤,充分的肿瘤切除是治愈的唯一机会。鉴于转换率相对较高及其相关的生存不良,对于已知或疑似 ACC,开放性切除应被视为标准治疗。